Tetanus and diphtheria toxoids adsorbed - Biologic Drug Details

Summary for tetanus and diphtheria toxoids adsorbed

Tradenames:	3
High Confidence Patents:	0
Applicants:	3
BLAs:	3
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for tetanus and diphtheria toxoids adsorbed

Recent Clinical Trials for tetanus and diphtheria toxoids adsorbed

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Servier	Phase 1
Katy Peters, MD, PhD	Phase 1
Gary Archer Ph.D.	Phase 2

See all tetanus and diphtheria toxoids adsorbed clinical trials

Pharmacology for tetanus and diphtheria toxoids adsorbed

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Clostridium Tetani Vaccine Inactivated Corynebacterium Diphtheriae Vaccine
Chemical Structure	Diphtheria Toxoid Tetanus Toxoid Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for tetanus and diphtheria toxoids adsorbed Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for tetanus and diphtheria toxoids adsorbed Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi Pasteur Limited	TENIVAC	tetanus and diphtheria toxoids adsorbed	Injection	103171	6,051,245	2018-12-15	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	TENIVAC	tetanus and diphtheria toxoids adsorbed	Injection	103171	7,208,160	2023-08-26	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	TENIVAC	tetanus and diphtheria toxoids adsorbed	Injection	103171	7,374,756	2027-05-14	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	TENIVAC	tetanus and diphtheria toxoids adsorbed	Injection	103171	7,723,074	2029-01-06	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for tetanus and diphtheria toxoids adsorbed Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for tetanus and diphtheria toxoids adsorbed

Country	Patent Number	Estimated Expiration
Brazil	PI0418335
Argentina	061538
South Korea	20060105877
Japan	2013252147

Overview of Market Dynamics and Financial Trajectory for the Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine

Last updated: February 14, 2026

The Td vaccine remains an essential component of adult immunization programs, especially for booster doses of tetanus and diphtheria. Its stability, established manufacturing pathways, and long-standing use in public health frameworks underpin its market fertility.

Market Size and Growth Drivers

The global market for Td vaccines was valued at approximately $350 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of approximately 4% from 2023 to 2030, reaching nearly $510 million by 2030.

Key growth drivers include:

• Aging Population: Increasing numbers of adults and elderly populations elevate demand for booster immunizations.
• Vaccination Policies: Many countries maintain or strengthen adult immunization programs including Td boosters.
• Pandemic Influence: While primarily affecting Covid-19 vaccine markets, the increased emphasis on vaccination infrastructure benefits booster vaccines including Td.
• Manufacturing Consolidation: A small number of multinational companies dominate production, reducing diversification but ensuring reliability of supply.

Manufacturers and Market Share

Major manufacturers include:

• Sanofi Pasteur: Largest with approximately 50% market share
• GlaxoSmithKline (GSK): About 30%
• Others (like Merck & Co., Serum Institute of India): Around 20%

Pricing and Revenue Trends

Wholesale prices for Td vaccines vary internationally, generally in the range of $0.50 to $2 per dose. In high-income markets (e.g., North America, EU), prices tend toward the higher end of this spectrum. Emerging markets may see prices as low as $0.20-$0.50 due to lower healthcare spending and local manufacturing.

Annual revenues for the segment are expected to increase steadily, supported by demand stabilization and expansion in immunization initiatives, especially in Asia and Africa, where immunization coverage improves.

Regulatory Landscape and Impact

Regulations for Td vaccines are well-established, with dossiers approved by agencies like the FDA, EMA, and WHO prequalification. The long approval timelines and established safety profiles enable sustained production without significant regulatory delays.

Emerging regulatory focus on vaccine safety reaffirms the importance of manufacturing quality control but does not significantly alter market entry barriers.

R&D and Innovation Outlook

Innovations in adjuvation and formulation have been limited for Td, given its mature status. However, efforts to develop combination vaccines incorporating diphtheria and tetanus toxoids with other antigens (e.g., combined meningococcal, hepatitis B) could influence future market trajectories.

Such combinations can improve compliance but may consolidate market share among leading vaccine manufacturers. From a pipeline perspective, no major breakthroughs or next-generation variants are reported for Td specifically.

Pricing and Reimbursement Policies

Markets with strong healthcare support policies tend to reimburse adult booster doses, securing stable revenues. In countries with private markets, direct-to-consumer marketing influences pricing but remains limited due to the vaccine’s established role and low cost.

Market Constraints and Risks

• Supply Chain Disruptions: Manufacturing reliance on specific bioreactors and ODM partnerships could pose risks.
• Vaccine Hesitancy: Misinformation and declining adult vaccine uptake could hinder demand growth.
• Regulatory Changes: Stricter safety requirements, particularly post-COVID, could entail increased compliance costs.

Financial Outlook

The mature status of the Td segment implies stable but limited segment growth. Manufacturers with efficiencies in production and distribution will benefit most from incremental demand increases.

Firms investing in combination vaccines may capture a larger market share, especially where compliance with booster regimens improves through integrated formulations.

Key Takeaways

• The global Td vaccine market is approximately $350 million as of 2022, with steady growth projected at 4% CAGR through 2030.

• Major players include Sanofi Pasteur and GSK, controlling roughly 80% combined market share.

• The vaccine's mature status offers stable revenues, with growth driven by aging populations, immunization policies, and global health initiatives.

• No significant innovation pipeline exists; focus remains on manufacturing efficiencies and combination formulations.

• Price sensitivity varies by region; low-cost supply in emerging markets supports ongoing demand.

FAQs

1. What factors most influence the growth of the Td market?
   Demographic trends, immunization policies, and global health efforts are primary drivers. Aging populations increase demand, and government programs reinforce booster scheduling.

2. Who dominates the global Td vaccine market?
   Sanofi Pasteur holds the largest share, followed by GSK. They control approximately 80% of the market combined.

3. What are the main risks facing the Td vaccine market?
   Supply chain disruptions, vaccine hesitancy, and evolving regulatory standards pose risks to steady revenue streams.

4. Are new developments expected in the Td vaccine space?
   Innovation is limited; most efforts focus on combination vaccines and manufacturing efficiencies rather than novel formulations.

5. How does pricing vary globally, and what are the implications?
   Prices range from $0.20 to $2 per dose depending on the region. Low prices in emerging markets sustain demand, whereas higher prices in developed countries support profitability.

Sources

[1] MarketResearch.com. (2022). Global Tetanus and Diphtheria Toxoids Market Analysis.
[2] WHO. (2022). Immunization Coverage Data.
[3] Sanofi, GSK Annual Reports, 2022.
[4] IQVIA. (2023). Vaccine Market Dynamics.